Cargando…
Impact of Biologics on SARS-COV-2 Disease Course When Infused Within 2 Weeks of Acquiring the Infection Among IBD Patients
SARS-CoV-2 was first identified in Wuhan in December 2019 and since then it has progressed into a pandemic that evolves continuously.(1) As of May 5, 2022, there have been more than 81 million cases and 994,187 deaths in the United States.(2) Inflammatory bowel disease (IBD) is a chronic inflammator...
Autores principales: | Khan, Nabeel, Patel, Manthankumar, Sundararajan, Ramaswamy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
W.B. Saunders for the American Gastroenterological Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404074/ https://www.ncbi.nlm.nih.gov/pubmed/36029967 http://dx.doi.org/10.1016/j.cgh.2022.08.017 |
Ejemplares similares
-
Incidence of Long COVID and Impact of Medications on the Risk of Developing Long COVID in a Nationwide Cohort of IBD Patients
por: Khan, Nabeel, et al.
Publicado: (2023) -
Adverse Events Related to SARS-CoV-2 Vaccine in a Nationwide Cohort of Patients With Inflammatory Bowel Disease
por: Mahmud, Nadim, et al.
Publicado: (2022) -
Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System
por: Khan, Nabeel, et al.
Publicado: (2021) -
Endoscopy in IBD: When and How?
por: Daperno, Marco
Publicado: (2023) -
The Impact of PPARγ Genetic Variants on IBD Susceptibility and IBD Disease Course
por: Mwinyi, Jessica, et al.
Publicado: (2012)